Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.990
+0.110 (5.85%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Cardiff Oncology Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 136 | 189 | 289 | 66 | 63 | 252 | |
| Market Cap Growth | -43.38% | -34.44% | 336.64% | 5.71% | -75.20% | -60.31% | |
| Enterprise Value | 79 | 130 | 233 | -13 | -49 | 121 | |
| Last Close Price | 1.99 | 2.81 | 4.34 | 1.48 | 1.40 | 6.01 | |
| PS Ratio | 229.42 | 319.20 | 422.72 | 135.50 | 162.04 | 702.51 | |
| PB Ratio | 2.99 | 4.17 | 3.48 | 0.95 | 0.59 | 1.80 | |
| P/TBV Ratio | 3.00 | 4.17 | 3.48 | 0.95 | 0.59 | 1.80 | |
| EV/Sales Ratio | 132.50 | 218.72 | 340.75 | - | - | 338.28 | |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Net Debt / Equity Ratio | -1.27 | -1.27 | -1.09 | -1.04 | -0.96 | -0.98 | |
| Net Debt / EBITDA Ratio | 1.18 | 1.18 | 1.87 | 1.61 | 2.59 | 4.85 | |
| Net Debt / FCF Ratio | 1.51 | 1.51 | 2.39 | 2.31 | 2.95 | 5.92 | |
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| Quick Ratio | 3.59 | 3.59 | 6.92 | 7.25 | 13.58 | 21.55 | |
| Current Ratio | 3.67 | 3.67 | 7.08 | 7.42 | 14.25 | 22.28 | |
| Return on Equity (ROE) | -71.45% | -71.45% | -59.51% | -47.07% | -31.37% | -21.07% | |
| Return on Assets (ROA) | -38.47% | -38.47% | -34.01% | -28.69% | -18.77% | -12.69% | |
| Return on Capital Employed (ROCE) | -107.60% | -107.60% | -58.10% | -63.80% | -36.80% | -20.20% | |
| Earnings Yield | -33.72% | -24.22% | -15.74% | -62.67% | -61.88% | -11.22% | |
| FCF Yield | -27.91% | -20.06% | -13.08% | -47.59% | -55.68% | -9.22% | |
| Buyback Yield / Dilution | -40.27% | -40.27% | -6.65% | -2.47% | -11.71% | -86.97% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.